Immunicon Corporation Achieves Endpoint In Its Pivotal Clinical Trial In Metastatic Androgen-Independent Prostate Cancer

HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) announced today that the Company met its primary endpoint associated with its pivotal clinical trial in metastatic androgen-independent prostate cancer. The primary endpoint was that circulating tumor cells (CTC) levels three-to-five weeks after the initiation of chemotherapy would predict overall survival. The study also showed that CTC levels predict overall survival at each of the tested time points.

MORE ON THIS TOPIC